Immuron does not anticipate any material impact from the recently announced US tariffs on pharmaceutical productsTravelan® Clinical Study: Topline results from the Travelan® clinical study conducted ...
New antibiotics are not being developed quickly enough to keep pace with the rapid spread of superbugs, a new report from the ...
The Paediatric Committee (PDCO) of the European Medicines Agency issued a positive opinion on Acurx's Pediatric Investigation Plan (PIP) for ibezapolstat ...
Lakewood-Amedex Biotherapeutics Inc., a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, ...
Two case studies highlight how naturopathic medicine supported long-term remission in chronic, recurrent C. difficile ...
Vibativ ® treats patients with pneumonia and serious skin infections NASHVILLE, Tenn. and RIYADH, Saudi Arabia, Sept. 29, 2025 /PRNewswire/ -- Specialty pharmaceutical companies Tabuk Pharmaceutical ...
TipRanks on MSN
Immuron Limited Advances Clinical and Commercial Initiatives
Immuron Limited ( ($AU:IMC) ) just unveiled an update. Immuron Limited announced several key updates, including the anticipated topline results of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback